Evidence map›Paper›PMID 36972550›Full record

ArticleAnalytical chemistry2023

Mix-and-Read Nanobody-Based Sandwich Homogeneous Split-Luciferase Assay for the Rapid Detection of Human Soluble Epoxide Hydrolase.

Qiyi He, Mark R McCoy, Huiyi Yang, Mingxia Lin, Xiping Cui, Suqing Zhao, Christophe Morisseau, Dongyang Li, Bruce D Hammock

Open access · greenAbstract read
In one paragraph

Article in Analytical chemistry, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
2.8field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 2 countries.

Qiyi HeDepartment of Entomology and Nematology and UCD Comprehensive Cancer Center, University of California Davis, Davis, California 95616, United States.
Mark R McCoyDepartment of Entomology and Nematology and UCD Comprehensive Cancer Center, University of California Davis, Davis, California 95616, United States.
Huiyi YangDepartment of Entomology and Nematology and UCD Comprehensive Cancer Center, University of California Davis, Davis, California 95616, United States.
Mingxia LinDepartment of Pharmaceutical Engineering, School of Biomedical and Pharmaceutical Sciences, Guangdong University of Technology, Guangzhou 510006, China.
Xiping CuiDepartment of Pharmaceutical Engineering, School of Biomedical and Pharmaceutical Sciences, Guangdong University of Technology, Guangzhou 510006, China.
Suqing ZhaoDepartment of Pharmaceutical Engineering, School of Biomedical and Pharmaceutical Sciences, Guangdong University of Technology, Guangzhou 510006, China.ORCID 0000-0002-8458-671X
Christophe MorisseauDepartment of Entomology and Nematology and UCD Comprehensive Cancer Center, University of California Davis, Davis, California 95616, United States.
Dongyang LiDepartment of Entomology and Nematology and UCD Comprehensive Cancer Center, University of California Davis, Davis, California 95616, United States.
Bruce D HammockDepartment of Entomology and Nematology and UCD Comprehensive Cancer Center, University of California Davis, Davis, California 95616, United States.ORCID 0000-0003-1408-8317
Guangdong University of Technology · CNUniversity of California, Davis · USZhejiang University · CN

Funding

Workshop on Environmental Technology Transfer and EntrepreneurshipP42ES004699 · NIEHS · UNIVERSITY OF CALIFORNIA DAVIS · PI YOUNG, THOMAS MICHAEL · 1987 to 2021
$50.1M
UC Davis CounterACT Center of Excellence: Developing Therapeutic Strategies for Mitigating the Chronic Neurological Consequences of Acute Organophosphate IntoxicationU54NS127758 · NINDS · UNIVERSITY OF CALIFORNIA AT DAVIS · PI Amy R. Brooks-Kayal, Pamela J Lein · 2022 to 2026
$17.2M
Supplement for bioactive lipids as effectors and indicators of the deleterious effects of human healthR35ES030443 · NIEHS · UNIVERSITY OF CALIFORNIA AT DAVIS · PI MORISSEAU, CHRISTOPHE HP · 2019 to 2025
$5.8M
NIEHS NIH HHS P42 ES004699NIEHS NIH HHS R35 ES030443NINDS NIH HHS U54 NS127758
6 · The paper itself

Abstract

The soluble epoxide hydrolase (sEH) is possibly both a marker for and target of numerous diseases. Herein, we describe a homogeneous mix-and-read assay for the detection of human sEH based on using split-luciferase detection coupled with anti-sEH nanobodies. Selective anti-sEH nanobodies were individually fused with NanoLuc Binary Technology (NanoBiT), which consists of a large and small portion of NanoLuc (LgBiT and SmBiT, respectively). Different orientations of the LgBiT and SmBiT-nanobody fusions were expressed and investigated for their ability to reform the active NanoLuc in the presence of the sEH. After optimization, the linear range of the assay could reach 3 orders of magnitude with a limit of detection (LOD) of 1.4 ng/mL. The assay has a high sensitivity to human sEH and reached a similar detection limit to our previously reported conventional nanobody-based ELISA. The procedure of the assay was faster (30 min total) and easy to operate, providing a more flexible and simple way to monitor human sEH levels in biological samples. In general, the immunoassay proposed here offers a more efficient detection and quantification approach that can be easily adapted to numerous macromolecules.

Indexed as

Single-Domain AntibodiesAnimalsCalibrationEpoxide HydrolasesHumansLuciferasesMiceRatsSolubilityTime FactorsEpoxide HydrolasesLuciferasesSingle-Domain Antibodies

Identifiers

PMID36972550
PMCPMC10335774
OpenAlexW4360991423

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.